|
|
Blood, 1 June 2008, Vol. 111, No. 11, pp. 5326-5333.
Prepublished online as a Blood First Edition Paper on February 15, 2008; DOI 10.1182/blood-2007-09-113050.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Christian S. Hinrichs*,1,
Rosanne Spolski*,2,
Chrystal M. Paulos1,
Luca Gattinoni1,
Keith W. Kerstann1,
Douglas C. Palmer1,
Christopher A. Klebanoff1,
Steven A. Rosenberg1,
Warren J. Leonard ,2, and
Nicholas P. Restifo ,1
1 National Cancer Institute (NCI), Surgery Branch, National Institutes of Health (NIH), Bethesda, MD; and
2 National Heart, Lung and Blood Institute (NHLBI), Laboratory of Molecular Immunology, NIH, Bethesda, MD
IL-2 and IL-21 are closely related cytokines that might have arisen by gene duplication. Both cytokines promote the function of effector CD8+ T cells, but their distinct effects on antigen-driven differentiation of naive CD8+ T cells into effector CD8+ T cells are not clearly understood. We found that antigen-induced expression of Eomesodermin (Eomes) and maturation of naive CD8+ T cells into granzyme B- and CD44-expressing effector CD8+ T cells was enhanced by IL-2, but, unexpectedly, suppressed by IL-21. Furthermore, IL-21 repressed expression of IL-2Ra and inhibited IL-2–mediated acquisition of a cytolytic CD8+ T-cell phenotype. Despite its inhibitory effects, IL-21 did not induce anergy, but instead potently enhanced the capacity of cells to mediate tumor regression upon adoptive transfer. In contrast, IL-2 impaired the subsequent antitumor function of transferred cells. Gene expression studies revealed a distinct IL-21 program that was characterized phenotypically by increased expression of L-selectin and functionally by enhanced antitumor immunity that was not reversed by secondary in vitro stimulation with antigen and IL-2. Thus, the efficacy of CD8+ T cells for adoptive immunotherapy can be influenced by opposing differentiation programs conferred by IL-2 and IL-21, a finding with important implications for the development of cellular cancer therapies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
IL-21 priming enhances T-cell immunotherapy
- Phillip K. Darcy
Blood 2008 111: 5268-5269.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
C. S. Hinrichs, Z. A. Borman, L. Cassard, L. Gattinoni, R. Spolski, Z. Yu, L. Sanchez-Perez, P. Muranski, S. J. Kern, C. Logun, et al.
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
PNAS,
October 13, 2009;
106(41):
17469 - 17474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Klebanoff, Z. Yu, L. N. Hwang, D. C. Palmer, L. Gattinoni, and N. P. Restifo
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination
Blood,
August 27, 2009;
114(9):
1776 - 1783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Hinrichs, A. Kaiser, C. M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z. A. Borman, P. Muranski, and N. P. Restifo
Type 17 CD8+ T cells display enhanced antitumor immunity
Blood,
July 16, 2009;
114(3):
596 - 599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. S. Johnson and S. C. Jameson
A Chronic Need for IL-21
Science,
June 19, 2009;
324(5934):
1525 - 1526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Hagge, B. M. Saunders, G. J. Ebenezer, N. A. Ray, V. T. Marks, W. J. Britton, J. L. Krahenbuhl, and L. B. Adams
Lymphotoxin-{alpha} and TNF Have Essential but Independent Roles in the Evolution of the Granulomatous Response in Experimental Leprosy
Am. J. Pathol.,
April 1, 2009;
174(4):
1379 - 1389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville, and E. Scotet
IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human V{gamma}9V{delta}2 T Cells for Adoptive Immunotherapy
J. Immunol.,
March 15, 2009;
182(6):
3423 - 3431.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|